Grace Therapeutics

Grace Therapeutics, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Grace Therapeutics, Inc. currently centers on drug candidates designed to address serious neurological and pain-related conditions, including GTx-104 for aneurysmal subarachnoid hemorrhage, GTx-102 for Ataxia-Telangiectasia, and GTx-101 for postherpetic neuralgia. The company works with proprietary drug-delivery technologies aimed at improving how established molecules are formulated and administered in clinical settings. Its portfolio is positioned at the intersection of specialty pharmaceuticals and rare-disease treatment, supporting hospitals, physicians, and patients managing complex unmet medical needs. Grace Therapeutics, Inc. is headquartered in Princeton, New Jersey.